Instinct Bio Technical Company Holdings Inc(BIOT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 5:49 PM ET (Korea 10/30 06:49)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.18 | Insider Own | 57% | Shs Outstand | 28.8M | Perf Week | -5.38% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 12.4M | Perf Month | -48.11% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 0.87% | Perf Quarter | -58.98% |
| Income | -0.00B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.16 | Perf Half Y | -97.85% |
| Sales | 0.00B | P/B | 2.05 | EPS next 5Y | - | ROA | -99.87% | Short Interest | 0.11M | Perf YTD | -98.42% |
| Book/sh | 0.09 | P/C | 185.79 | EPS past 3/5Y | - -416.29% | ROE | - | 52W High | -99.61% ($50.00) | Perf Year | -98.42% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | -36.1% | 52W Low | 16.63% ($0.17) | Perf 3Y | -98.42% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -17.05% | Gross Margin | - | Volatility(W/M) | 16.26% 13.59% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.36 | EPS Q/Q | 95.72% | Profit Margin | - | RSI (14) | 30.61 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.61 | Sales Q/Q | - | SMA20 | -31.04% ($0.28) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | 0.08 | Earnings | - | SMA50 | -45.62% ($0.35) | Rel Volume | 0.23 | Prev Close | $0.19 |
| Employees | 2 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | - | SMA200 | -97.24% ($6.88) | Avg Volume(3M) | 0.67M | Price | $0.19 |
| IPO | 2022/4/4 | Option/Short | No/Yes | Trades | 232 | Volume | 152,906 | Change | 2.6% |
A healthcare company that operates both stem cell-based regenerative medicine technologies and premium skincare and wellness brands. Headquartered in Tokyo, Japan, it has a vertically integrated structure spanning research, in-house manufacturing, and consumer brand sales, and is pursuing expansion into overseas markets with Asia as its base.
Over the past 1 year, on the lower side
100% below its 1-year high.
Traded less than usual. That is 23% of its average volume.
BIOT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -98.4%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
IBB iShares Biotechnology ETF 11.5B 
XBI State Street SPDR S&P Biotech ETF 10.8B 
FBT First Trust NYSE Arca Biotechnology Index Fund 3.1B 
PBPH Portfolio Building Block World Pharma and Biotech Index ETF 1.1B 
LABU Direxion Daily S&P Biotech Bull 3X ETF 669M It ranks #29 of 30 in the industry
Based on market cap of $6M.
DSY#26 Big Tree Cloud Holdings Ltd $17M PER - 
ATTT#27 Atlas Trinity Tech Ltd $15M PER 2.9 
TANH#28 Tantech Holdings Ltd $8M PER 0.5 BIOT#29 Instinct Bio Technical Company Holdings Inc $6M PER - 
BYAH#30 Park Ha Biological Technology Co Ltd $5M PER - 
FAQ
What kind of company is BIOT?
BIOT belongs to the Consumer Defensive sector and operates in the Household & Personal Products industry.
What is the market cap of BIOT?
The market cap of BIOT is approximately $6M, ranking 5,595 within its sector.
What is the 52-week high and low for BIOT?
BIOT has recorded a 52-week high of $50.00 and a low of $0.17.
